A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL-40/Interleukin-13 Receptor α2 Axis.
Aorta
/ metabolism
Chitinase-3-Like Protein 1
/ metabolism
Giant Cell Arteritis
/ metabolism
Granulocyte-Macrophage Colony-Stimulating Factor
/ pharmacology
Humans
Interleukin-13 Receptor alpha2 Subunit
/ metabolism
Macrophage Colony-Stimulating Factor
/ pharmacology
Macrophages
/ drug effects
Matrix Metalloproteinase 9
/ metabolism
Neovascularization, Pathologic
/ metabolism
Signal Transduction
/ drug effects
Temporal Arteries
/ metabolism
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
09
11
2020
accepted:
27
05
2021
pubmed:
10
6
2021
medline:
19
1
2022
entrez:
9
6
2021
Statut:
ppublish
Résumé
Macrophages mediate inflammation, angiogenesis, and tissue destruction in giant cell arteritis (GCA). Serum levels of the macrophage-associated protein YKL-40 (chitinase 3-like protein 1), previously linked to angiogenesis and tissue remodeling, remain elevated in GCA despite glucocorticoid treatment. This study was undertaken to investigate the contribution of YKL-40 to vasculopathy in GCA. Immunohistochemistry was performed on GCA temporal artery biopsy specimens (n = 12) and aortas (n = 10) for detection of YKL-40, its receptor interleukin-13 receptor α2 (IL-13Rα2), macrophage markers PU.1 and CD206, and the tissue-destructive protein matrix metalloproteinase 9 (MMP-9). Ten noninflamed temporal artery biopsy specimens served as controls. In vitro experiments with granulocyte-macrophage colony-stimulating factor (GM-CSF)- or macrophage colony-stimulating factor (M-CSF)-skewed monocyte-derived macrophages were conducted to study the dynamics of YKL-40 production. Next, small interfering RNA-mediated knockdown of YKL-40 in GM-CSF-skewed macrophages was performed to study its effect on MMP-9 production. Finally, the angiogenic potential of YKL-40 was investigated by tube formation experiments using human microvascular endothelial cells (HMVECs). YKL-40 was abundantly expressed by a CD206+MMP-9+ macrophage subset in inflamed temporal arteries and aortas. GM-CSF-skewed macrophages from GCA patients, but not healthy controls, released significantly higher levels of YKL-40 compared to M-CSF-skewed macrophages (P = 0.039). In inflamed temporal arteries, IL-13Rα2 was expressed by macrophages and endothelial cells. Functionally, knockdown of YKL-40 led to a 10-50% reduction in MMP-9 production by macrophages, whereas exposure of HMVECS to YKL-40 led to significantly increased tube formation. In GCA, a GM-CSF-skewed, CD206+MMP-9+ macrophage subset expresses high levels of YKL-40 which may stimulate tissue destruction and angiogenesis through IL-13Rα2 signaling. Targeting YKL-40 or GM-CSF may inhibit macrophages that are currently insufficiently suppressed by glucocorticoids.
Identifiants
pubmed: 34105308
doi: 10.1002/art.41887
pmc: PMC9298326
doi:
Substances chimiques
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
Interleukin-13 Receptor alpha2 Subunit
0
Macrophage Colony-Stimulating Factor
81627-83-0
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2327-2337Subventions
Organisme : Abel Tasman Talent Program
Organisme : ReumaNederland
ID : 14-3-401
Informations de copyright
© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Exp Mol Med. 2009 Apr 30;41(4):259-68
pubmed: 19299915
Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii22-ii31
pubmed: 29982780
Circ Res. 2018 Aug 31;123(6):700-715
pubmed: 29970365
FASEB J. 2017 Oct;31(10):4370-4381
pubmed: 28637652
Ann Intern Med. 1994 Oct 1;121(7):484-91
pubmed: 8067646
Int J Cancer. 2012 Jul 15;131(2):377-86
pubmed: 21866546
J Biol Chem. 2011 Apr 29;286(17):15332-43
pubmed: 21385870
Structure. 2010 Mar 10;18(3):332-42
pubmed: 20223216
Genes Cells. 2003 Jun;8(6):515-23
pubmed: 12786942
J Allergy Clin Immunol. 2014 Oct;134(4):975-8.e5
pubmed: 24954262
Blood. 2006 Apr 15;107(8):3221-8
pubmed: 16357325
Autoimmun Rev. 2017 Aug;16(8):833-844
pubmed: 28564617
Circulation. 2002 Sep 24;106(13):1664-71
pubmed: 12270860
J Leukoc Biol. 2015 Dec;98(6):931-6
pubmed: 26310833
Am J Pathol. 1999 Sep;155(3):765-74
pubmed: 10487834
J Leukoc Biol. 2014 May;95(5):797-808
pubmed: 24399840
BMC Immunol. 2010 Jun 21;11:30
pubmed: 20565954
Sci Rep. 2017 Jul 26;7(1):6553
pubmed: 28747747
Mol Cancer Ther. 2011 May;10(5):742-51
pubmed: 21357475
Nat Med. 2006 Jan;12(1):99-106
pubmed: 16327802
Oncogene. 2009 Dec 17;28(50):4456-68
pubmed: 19767768
Arthritis Rheum. 2003 Dec;48(12):3522-31
pubmed: 14674004
Mod Pathol. 2017 Jun;30(6):788-796
pubmed: 28256573
Clin Transl Immunology. 2020 Aug 27;9(9):e1164
pubmed: 32884747
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
J Transl Med. 2018 Dec 20;16(1):369
pubmed: 30572904
Allergy. 2018 Aug;73(8):1673-1685
pubmed: 29405354
Arthritis Rheumatol. 2014 Jul;66(7):1927-38
pubmed: 24623536
Am J Respir Crit Care Med. 2010 Sep 15;182(6):805-18
pubmed: 20522789
Sci Rep. 2020 Jan 23;10(1):1017
pubmed: 31974500
Eur J Immunol. 2018 Aug;48(8):1329-1335
pubmed: 29677387
Respir Res. 2015 Dec 22;16:154
pubmed: 26696093
J Leukoc Biol. 2011 Oct;90(4):761-9
pubmed: 21742938
Arthritis Rheumatol. 2019 Aug;71(8):1329-1338
pubmed: 30835950
Rheumatology (Oxford). 2019 Feb 25;:
pubmed: 30805622
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4596-4605
pubmed: 31675076
Rheumatology (Oxford). 2018 Oct 1;57(10):1795-1801
pubmed: 29961816
Circulation. 2010 Feb 23;121(7):906-15
pubmed: 20142449
Arthritis Rheum. 1999 Dec;42(12):2624-30
pubmed: 10616010
Rheumatology (Oxford). 2018 Jun 1;57(6):982-986
pubmed: 29529280
Toxicol Appl Pharmacol. 2012 Apr 1;260(1):89-94
pubmed: 22326992
Medicine (Baltimore). 2004 Nov;83(6):335-341
pubmed: 15525845
Cell Rep. 2013 Aug 29;4(4):830-41
pubmed: 23972995